Benmelstobart in Recurrent Cervical Cancer: NCT07472153 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2/3
Clinical phase
Recruiting
Recruitment status
120
Planned enrollment
2030-06-30
Primary-completion proxy
Executive view
NCT07472153 evaluates Benmelstobart in Recurrent Cervical Cancer. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is Belarus. The first listed primary endpoint is Overall survival, assessed over From enrollment through study completion, an average of 2 year.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07472153 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Recurrent Cervical Cancer landscape. Drug & Asset MCP drug_fetch was queried for Benmelstobart, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07472153 | Benmelstobart | Phase 2/3 / Recruiting | Sponsor not reported | Belarus | Overall survival From enrollment through study completion, an average of 2 year | 2030-06-30 |
| NCT07466901 | Famitinib Malate | Not Applicable / Not yet recruiting | Fudan University | China | 2-year disease-free survival rate 2 years after treatment | 2030-04-01 |
| NCT07454642 | AVA-6103 | Phase 1 / Recruiting | Avacta Life Sciences Ltd. | United States | Adverse events (AEs) From Day 1 until up to 30 days after last dose of study drug. | 2029-01-01 |
| NCT07433283 | CNSI-Fe | Phase 1/2 / Recruiting | Sichuan Yingrui Pharmaceutical Technology Co., Ltd. | China | Incidence and severity of participants with treatment-related adverse events as assessed by CTCAE v5.0 From enrollment to the end of treatment at 12 weeks | 2026-12-31 |
| NCT07424664 | Zimberelimab | Phase 2 / Recruiting | Wuhan Xiehe Hospital Tower | China | The objective response rate of the treatment Up to approximately 36 months | 2027-03-15 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07472153 is a Phase 2/3, recruiting study with 120 planned participants. Allocation is Randomized, masking is Single, and the intervention model is Parallel Assignment.
The primary endpoint is “Overall survival” over “From enrollment through study completion, an average of 2 year.” The retrieved endpoint description is: Time from randomization to the death of any cause.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 120 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Bevacizumab as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Recurrent Cervical Cancer. These records do not establish direct evidence for NCT07472153 unless the registration number matches.
Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV
Not Applicable; n=180; Number of Participants Retained in the Study Through Week 24: Risk Difference (RD) = -6.7(95% CI, -14.4 to -0.5); Number of Participants Retained in the Study Through Week 24: Risk Difference (RD) = -6.7(95% CI, -14.4 to -0.5) Source: https://clinicaltrials.gov/ct2/show/results/NCT05413811
Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects With HPV Positive Cancers
Phase 1/2; n=39; Phase I: Recommended Phase II Dose of PRGN-2009 = 500,000,000,000 viral particles (VP) Source: https://clinicaltrials.gov/ct2/show/results/NCT04432597
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhib…
Phase 1/2; n=97; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 62 Participants ; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 3 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05572684
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Benmelstobart is indexed as Monoclonal antibody with PDL1 biology and a global stage of Approved. The asset profile lists Zhejiang Crownmab Biotech Co. Ltd. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Benmelstobart is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07472153
Protocol source: https://clinicaltrials.gov/study/NCT07472153
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Benmelstobart in Recurrent Cervical Cancer is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Overall survival and 2030-06-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
